During the recent earnings call, Dr. Chava shared that ImmunoACT, a Laurus Labs subsidiary, will have the capacity to treat 2,500 patients annually by Sep 2025 for its CAR-T cell therapy. The therapy, branded as NexCAR19, is priced between ₹30 lakh and ₹40 lakh (approximately USD 36,000 to 48,000) per patient. This pricing is nearly one-tenth of the global cost for similar CAR-T treatments, which can go up to ₹4 crore (around USD 500,000). Based on a price assumption of ₹30 lakh per patient, ImmunoACT could generate annual revenue of approximately ₹750 crore.
16 Likes